Abstract
ObjectiveTo examine the design characteristics, risk of bias, and reporting adequacy of pivotal randomised controlled trials of cancer drugs approved by the European Medicines Agency (EMA).DesignCross sectional analysis.SettingEuropean regulatory documents,...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have